Psyence Biomedical Ltd. NEW YORK, Dec. 27, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence Biomed” or the “Company”) today announced that it has closed its ...

NEW YORK, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence Biomed” or the “Company”) today announced that it has received notice from the Nasdaq Hearings ...

NEW YORK, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) ("Psyence Biomed” or the "Company") today announced that it has entered into definitive agreements for the purchase ...

Psyence Biomedical (PBM) has entered into definitive agreements for the purchase and sale of an aggregate of 1,000,000 common shares series A common warrants to purchase up to 1,000,000 common ...

Psyence Biomedical Ltd. has completed a private placement, raising approximately $2 million by selling 1,000,000 common shares along with series A and series B common warrants, with an exercise ...

Psyence Biomedical Ltd. announced that it has regained compliance with Nasdaq's continued listing requirements, as confirmed by the Nasdaq Hearings panel. Following a transfer to The Nasdaq ...

Psyence Biomedical Ltd. (PBM) stock price is 1.64 and Psyence Biomedical Ltd. (PBM) 10-day simple moving average is 1.68. Psyence Biomedical Ltd. (PBM) stock price is 1.64 and Psyence Biomedical Ltd.

TORONTO, Dec. 06, 2024 (GLOBE NEWSWIRE) -- Psyence Group Inc ("Psyence Group" or the "Company") (CSE: PSYG) hereby announces that it has entered into an addendum to the previously announced debt ...